Hypertension, Pulmonary study: TX000045
Official title Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
ClinicalTrials.gov ID: NCT07473700
What this study is testing
What is TX000045?
An investigational subcutaneous injectable medicine being studied for pulmonary hypertension secondary to interstitial lung disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether TX000045 can reduce the pressure in the lung blood vessels and how safe it is for people with pulmonary hypertension caused by interstitial lung disease.
- Who it's for
- You may be able to join if you have high lung blood pressure that comes from interstitial lung disease.
- What's involved
- You will receive the drug TX000045 and have your lung blood pressure checked during the study. You may also have other safety tests.
- Time commitment
- The study lasts about a few months and includes several visits to the clinic for checks and tests.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater...
- 40% predicted less than or equal to (\<=) forced vital capacity (FVC) \<= 80% predicted at screening
- At least ONE of the following is required to undergo the first screening visit: Documented diagnostic right heart catheterization (RHC) within 18...
You likely can't join if
- Participants have a confirmed or suspected diagnosis of pulmonary hypertension in World Health Organization (WHO) Group 1, WHO Group 2, WHO Group 4...
- Participants have received phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators, intravenous...
- Participants have any type of pulmonary and cardiovascular comorbidities as defined n protocol
- Participants who are taking disease-modifying therapy for the underlying interstitial lung disease (ILD) (anti-fibrotics, immunosuppressives, and...
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- San Francisco, California, United States
- Allen Park, Michigan, United States
- Wroclaw, Poland
- Bucharest, Romania
- Belgrade, Serbia
- Kamenitz, Serbia
- Niš, Serbia
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Madrid, Spain
- Santander, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; San Francisco, California, United States; Allen Park, Michigan, United States; Wroclaw, Poland; Bucharest, Romania; Belgrade, Serbia and 6 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.